Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92835 | 0.79 | CA12 (0.38) | CA12CA1CA7CA14ALDH1A1 | |
| SCHEMBL12807884 | 0.79 | CA1 (0.37) | CA12CA1CA7CA14SMN1; SMN2 | |
| SCHEMBL13627742 | 0.77 | CA12 (0.49) | CA12CA1CA7CA14ALDH1A1 | |
| SCHEMBL85214 | 0.76 | CA1 (0.43) | CA12CA1CA7CA14ALDH1A1 | |
| SCHEMBL14615842 | 0.72 | CA2 (0.50) | CA1ALDH1A1HTTSMN1; SMN2DHFR | |
| SCHEMBL24961528 | 0.71 | CA1 (0.33) | CA1ALDH1A1SMN1; SMN2DHFRTSHR | |
| SCHEMBL13940756 | 0.71 | CA12 (0.75) | CA12CA1CA7CA14LMNA | |
| Hydrochloric Acid SCHEMBL5498552 | 0.70 | CA2 (0.48) | CA1ALDH1A1HTTSMN1; SMN2DHFR | |
| SCHEMBL27925584 | 0.70 | PAOX (0.35) | ALDH1A1SMN1; SMN2DHFRTSHRTDP1 | |
| SCHEMBL4719324 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334894-A1 | Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334894-A1 | Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof | SLC10A1, FXR1, NR1H4 | CA12 3305/4885CA1 2031/4885CA7 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.